Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 23, 2017
Pharmacy Choice - News - Front Page Healthcare News - February 23, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/23/17 - A continual quest to meet the SWFL market's demands
"Obviously the focus is to deliver quality care all the time, while delivering a positive patient experience and being financially prudent," said Mr. Lowe, who has led the organization since December 2014. The health-care system consists of two hospitals: Physicians Regional Pine Ridge and Physicians Regional Collier Boulevard, a multi-specialty ph
2/23/17 - Absorbable Nasal Implant Devices Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024
Absorbable nasal implants are used to treat nasal blockage or obstructions and allow better breathing and sleep to the patient. Nasal airway obstruction can be caused by several factors, including septal deviation, enlarged turbinates, and weakened upper and/or lower lateral nasal wall cartilage, which can lead to nasal valve collapse.
2/23/17 - Achaogen Announces Achievement of a Key Milestone in Developing a Plazomicin Assay to Support Therapeutic Drug Management (TDM) [Tehran Times (Iran)]
-Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced that they have achieved a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin. Achaogen is developing plazomicin for...
2/23/17 - Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
2/23/17 - Aphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple Sclerosis [Sudan Tribune]
-Aphios Corporation today announced that it is spinning-off Aphios Pharma to develop FDA- approved, cannabis-based drugs for treating highly unmet Central Nervous System disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana.
2/23/17 - Arnot Health, Inc. Chooses Harris Healthcare Emergency Department Information System [Sport360]
In February, Harris Healthcare successfully implemented the initial Go Live phase with Arnot Health Ira Davenport Memorial Hospital ED. Harris Healthcare has a proven best in KLAS level EDIS and EHR integrated solution. Im pleased with the level of client support Harris Healthcare provided throughout the process.
2/23/17 - BD Veritor System Meets FDA's New Performance Requirements for Rapid Influenza Antigen Detection Tests
BD, a leading global medical technology company, today announced that its BD Veritor System Flu A+ B, a digital immunoassay for the rapid detection of influenza, meets the new FDA performance requirements.i. With the new FDA requirements, i rapid flu tests, which are used by health care providers and laboratory personnel, must now attain a higher l
2/23/17 - BioCorRx Provides Preclinical Study Update on BICX101 Development
Webcast Available at http://www.BioCorRx.comAnaheim, CA 02/23/2017 BioCorRx Inc., a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided an update on the preclinical development of BICX101, a new sustained release injectable naltrexone product for the treatment of substance abuse addic
2/23/17 - Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck's KEYTRUDA (pembrolizumab)
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
2/23/17 - Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain
LONDON, UK/ ACCESSWIRE/ February 23, 2017/ Active Wall St. blog coverage looks at the headline from Ocular Therapeutix, Inc. as the Company announced on February 22, 2017, that the Company's New Drug Application resubmission for DEXTENZA?, for the treatment of ocular pain occurring after ophthalmic surgery has been accepted as a filing for review
2/23/17 - Cadila Healthcare receives approval from USFDA [India Infoline News Service]
Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from Primary Biliary. Cadila Healthcare has received approval from US Food& Drug Administration to initiate Phase II clinical studies of Saroglitazar Magnesium in patients suffering from...
2/23/17 - Canon Virginia launches medical device manufacturing services [T-break Tech (Middle East)]
Toru Nishizawa, president and CEO of Canon Virginia said: The addition of medical device manufacturing extends Canons commitment, manufacturing expertise and established resources into the medical device industry. Ron Kurz, director of medical programme management said: We can provide individually tailored solutions to meet the unique needs of...
2/23/17 - Carolina Complete Health Network, Inc. to Conduct Public Offering of Stock
CCHN will primarily establish, build and maintain a network of providers to serve this patient-focused Medicaid health plan. CCHN has two classes of common stock: Class M Common Stock, which is held by the NCMS, and Class P Common Stock, which CCHN anticipates offering to physicians, nurse practitioners and physician assistants licensed to practice
2/23/17 - CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
2/23/17 - Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis [All Iraq News Agency (AIN)]
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
2/23/17 - Cheri Bustos: Repealing, replacing ACA easier said than done [Journal Star, Peoria, Ill.]
Feb. 22 PEORIA Oversimplified campaign rhetoric about repealing and replacing the Affordable Care Act discounts the complexity of America's health care industry, U.S. Rep. As Congressional Republicans craft legislation to replace former President Barack Obama's legacy law, Bustos made a stop at a Peoria supportive living community to bring atte
2/23/17 - China Exclusive: Chinese affordable lung cancer drug hits market [Philippines News Agency]
Its release ends an almost decade-long monopoly by Iressa, developed by British multinational biopharmaceutical company AstraZeneca and introduced to China in 2005.. Yiruike was approved for marketing by China's State Food and Drug Administration after Iressa's patent protection expired in April 2016, Qilu sources said. The drug is a much-needed fi
2/23/17 - Congressman Collins has a duty to interact with his constituents
As our elected "representative," Mr. Collins has a duty to listen to and interact with his constituents beyond his occasional one-sided form letter. Could Mr. Collins perhaps respect his constituents enough to understand that they have serious concerns about how their healthcare bills will be covered if the Affordable Care Act is gutted by his part
2/23/17 - Consumers Can Now See Which U.S. Surgeons Rate Best and Worst for Patient Outcomes Based on Analysis of Millions of Cases
WASHINGTON, Feb. 23, 2017/ PRNewswire-USNewswire/ Nonprofit Consumers' Checkbook/ Center for the Study of Services is releasing the names of the surgeons who based on the organization's in-depth analyses have the nation's best and worst outcomes in major surgeries. These analyses look at how often surgeons' patients die in hospital or withi
2/23/17 - Credence Research: Recent Release : Global Ultrasound-Guided High-intensity Focused Ultrasound System Market, Size, Share Regional Outlook 2017 - Acute Market Reports
This report studies sales of Ultrasound-Guided High- intensity Focused Ultrasound System in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering. Split by applications, this report focuses on sales, market share and growth rate of Ultrasound-Guided High- intensity Focused Ultrasound
2/23/17 - Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism The Blm Study
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
2/23/17 - Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
2/23/17 - Diagnostic Imaging Market Worth 36.43 Billion by 2021
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
2/23/17 - Dr. Daniel Spyker, Former FDA acting Deputy Division Director of Cardiovascular, Respiratory, and Neurological Devices, Joins NDA Partners [Sudan Tribune]
In Dr. Spykers accomplished career, he held positions as Senior Director of Drug Safety and Pharmacovigilance at Alexza Pharmaceuticals; Director, Pharmacokinetics and Pharmacodynamic Sciences, Genentech, where he established the clinical pharmacology unit; and Senior Medical Director, Clinical Risk Assessment and Coordination Department at Purdue.
2/23/17 - Durdans Laboratory Services adds on latest 'predicative tests' for 'disease prevention'
Durdans Laboratory Services, the fully-fledged laboratory arm of the Joint Commission International approved Durdans Hospital, whilst retaining its traditional Test Panel recently made available novel tests to keep up with modern developments in Laboratory Medicine. Noteworthy are the' predictive tests' whose outcomes can be utilised to avert' futu
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415